Interxion, a leading European provider of carrier-neutral colocation data centre services, today announced that Cancer Research UK, the world's leading charity dedicated to beating cancer through research, is locating its mission-critical data and applications in Interxion’s London data centre.

Cancer Research UK spent £355 million on research in 2008/09, funding the work of 4,800 world-class scientists, doctors and nurses. The IT department’s core purpose is to enable Cancer Research UK to beat cancer through the provision of world class information tools, IT systems and services.  
 
In 2008 the charity took the decision to outsource its data centre requirements after having compared the cost of retrofitting its own legacy data centre to using different types of colocation facilities. Early on the company realised that significant cost savings could be made by colocating its IT infrastructure with a specialist carrier-neutral operator. Interxion was chosen after a tender process in which all the colocation providers within the M25, that had both the space required and the ability to deliver within a set timescale, were invited to participate.

“The selection of Interxion and its secure robust environment, will meet our goals by improving the quality and delivery of many of our end-to-end IT services and driving down the cost.” said Jane Swindle, IS Business Change Manager at Cancer Research UK.

“It is great to see how the service we offer can generate operational benefits as well as savings for  such an important worldwide organisation,” said Greg McCulloch, MD of Interxion UK. “The fact that Cancer Research UK has entrusted us with its most valuable assets is a resounding endorsement of Interxion’s leading security environment and robust infrastructure.”